Clinical Trials Browser

OTHER × tocilizumab × 90 days × Clear all

NCT03821246 2026-06-04

Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

Phase 2 Recruiting

68 enrolled

Genitourinary

Prostatic Neoplasms

NCT03434730 2026-05-26

Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation

Phase 2 Completed

46 enrolled 8 charts

LymphoidMyeloidOther hematologic neoplasm

Hodgkin Disease, Leukemia, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases

NCT07594067 2026-05-18

TCR1188-ABC Cells in KRAS-mutated Cancers

Phase 1 Not yet recruiting

30 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Cholangiocarcinoma

NCT05846789 2026-05-08

SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers

Phase 2 Recruiting

168 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05233397 2026-04-23

ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

Phase 2 Recruiting

30 enrolled

CNS

Craniopharyngioma

NCT05972135 2026-04-22

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Phase 2 Recruiting

100 enrolled

Plasma cell

Cytokine Release Syndrome, Multiple Myeloma